Sunitinib

Sort by

(Z)-N-(2-(ethyl(nitroso)amino)ethyl)-5-((5-fluoro-...

  • CAT NUMBER DCTI-C-2467
  • CAS NUMBER NA
  • MOLECULAR FORMULA C20H22FN5O3
  • MOLECULAR WEIGHT 399.43

N-(2-(ethyl(nitroso)amino)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide

  • CAT NUMBER DCTI-C-2593
  • CAS NUMBER NA
  • MOLECULAR FORMULA C11H18N4O2
  • MOLECULAR WEIGHT 238.29

N-(2-(ethyl(nitroso)amino)ethyl)-5-formyl-2,4-dime...

  • CAT NUMBER DCTI-C-2468
  • CAS NUMBER NA
  • MOLECULAR FORMULA C12H18N4O3
  • MOLECULAR WEIGHT 266.3

N-(2-aminoethyl)-N-ethylnitrous amide

  • CAT NUMBER DCTI-C-2586
  • CAS NUMBER NA
  • MOLECULAR FORMULA C4H11N3O (Free Base); C6H11F3N3O2 (TFA Salt)
  • MOLECULAR WEIGHT 117.15 (Free Base); 214.17 (TFA Salt)

Sunitinib N-Oxide

  • CAT Number DCTI-C-1119
  • CAS Number 356068-99-0
  • Molecular Formula C22H27FN4O3
  • Molecular Weight 414.21

tert-butyl 4-((2-(ethyl(nitroso)amino)ethyl)carbam...

  • CAT NUMBER DCTI-C-2469
  • CAS NUMBER NA
  • MOLECULAR FORMULA C16H26N4O4
  • MOLECULAR WEIGHT 338.41

General Information

Sunitinib Impurities and Sunitinib  

Daicel Pharma is a reliable source for synthesizing high-quality Sunitinib impurities, (Z)-N-(2-(ethyl(nitroso)amino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide, N-(2-aminoethyl)-N-ethylnitrous amide, Sunitinib N-Oxide, etc. These impurities help in analyzing the quality, stability, and biological safety of the active pharmaceutical ingredient Sunitinib. Additionally, Daicel Pharma specializes in the custom synthesis of Sunitinib impurities, catering to specific client requirements. These high-quality impurities can be shipped globally, offering convenience and flexibility to customers worldwide.

Sunitinib [CAS: 557795-19-4] is a receptor tyrosine kinase (RTK) inhibitor for treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

Sunitinib: Use and Commercial Availability  

Sunitinib is a medication to treat a rare stomach cancer, bowel, or esophagus called a gastrointestinal stromal tumor (GIST). It also treats advanced renal cell carcinoma and a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET).

Sunitinib is available under Sutent, which contains the active ingredient, Sunitinib.

Sunitinib Structure and Mechanism of Action  Sunitinib Structure and Mechanism of Action

The chemical name of Sunitinib is N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide. Its chemical formula is C22H27FN4O2, and its molecular weight is approximately 398.47 g/mol.

Sunitinib inhibits multiple RTKs that cause tumor growth and cancer. It also has inhibitory action against platelet-derived growth factor receptors (PDGFRa and PDGFRb), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), and other kinases.

Sunitinib Impurities and Synthesis

During Sunitinib’s manufacturing1, impurities form that compromise its effectiveness. They can arise from various sources, including the raw materials, intermediates, and chemicals utilized to synthesize Sunitinib. Closely managing and monitoring these impurities is paramount to ensure the drug’s optimal efficacy and safety.

Daicel offers a Certificate of Analysis (CoA) for Sunitinib impurity standards, encompassing impurities such as (Z)-N-(2-(ethyl(nitroso)amino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide, N-(2-aminoethyl)-N-ethylnitrous amide, Sunitinib N-Oxide, etc. The CoA provides detailed characterization data, including 1H NMR, 13C NMR, IR, MASS, and HPLC purity2. Additionally, we give a detailed 13C-DEPT upon delivery. With advanced technology and expertise, Daicel can synthesize any unknown Sunitinib impurity or degradation product. We also supply labeled compounds.

References
FAQ's

Frequently Asked Questions

Impurities in Sunitinib can affect its quality, safety, and efficacy. Depending on the type and level of impurities, they can impact the drug's pharmacological activity and stability and pose potential risks to patient health.

Impurities in Sunitinib are detected and quantified using reversed-phase (RP) ultra-high-performance liquid chromatography. This method will allow for accurate identification and quantification of impurities.

To maintain control over impurity levels in Sunitinib, several strategies, like using high-quality starting materials, optimizing synthesis, comprehensive quality-control tests, and continuously monitoring impurity levels, must be implemented at different stages of the manufacturing process.

Sunitinib Impurities are stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart